Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MPT-0118 |
Synonyms | |
Therapy Description |
MPT-0118 inhibits mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which may result in reprogramming of regulatory T cells, potentially leading to inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021; Vol 9, Issue Suppl 2; Annals of Oncology 32 (2021): S857). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MPT-0118 | MPT0118|MPT 0118 | MPT-0118 inhibits mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which may result in reprogramming of regulatory T cells, potentially leading to inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021; Vol 9, Issue Suppl 2; Annals of Oncology 32 (2021): S857). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04859777 | Phase I | MPT-0118 + Pembrolizumab MPT-0118 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Unknown status | USA | 0 |